Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists

American Journal of Cardiovascular Drugs

Volumn 7, Issue 5, 2007, Pages 347-356

  Smith, David H G ^a  

^a Integrium   (United States)

Author keywords

Angiotensin receptor antagonists, therapeutic use; Dose response; Hypertension, treatment; Olmesartan medoxomil, therapeutic use

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN POTASSIUM; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REGISTRATION; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 35448992138     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707050-00004     Document Type: Review

References (36)

1. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004; 44: 398-404
2. Benetos A, Thomas F, Bean KE, et al. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21: 1635-40
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
4. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
5. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002; 40: 464-9
6. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007; 9: 187-95
7. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens 2005; 18: 287-94
8. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41-50
9. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861-6
10. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17: 252-9
11. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797-805
12. Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000; 22: 1186-203
13. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-26
14. Giles TD, Bakris GL, Smith DH, et al. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens 2003; 16: 460-6
15. Meredith PA. Is postural hypotension a real problem with antihypertensive medication? Cardiology 2001; 96 Suppl. 1: 19-24
16. Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001; 19: S41-8
17. Elmfeldt D, George M, Hubner R, et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11 Suppl. 2: S49-53
18. Reif M, White WB, Fagan TC, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1998; 82: 961-5
19. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998; 11: 445-53
20. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50
21. Pool J, Oparil S, Hedner T, et al. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998; 20: 1106-14
22. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-17
23. COZAAR (losartan potassium) [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc., 2005
24. Neutel JM, Smith DH, Weber MA, et al. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004; 6: 168-74
25. Neutel JM, Smith DH, Silfani TN, et al. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006; 20: 255-62
26. Written communication, Study Report 866-419. Parsippany (NJ): Daiichi Sankyo, Inc., 2007. (Data on file)
27. Izzo J, Neutel JM, Dubiel R, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens 2007; 9: 36-44
28. Izzo J, Neutel J, Dubiel R. Efficacy of olmesartan medoxomil and hydrochlorothiazide in achieving blood pressure control and normalization in stage 2 systolic hypertension [abstract]. Am J Hypertens 2005; 18: 64A
29. Guthrie R, Saini R, Herman T, et al. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension: a double-blind, placebo-controlled, dose-titration study. Clin Drug Invest 1998; 15: 217-27
30. Bell TP, DeQuattro V, Lasseter KC, et al. Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1999; 83: 272-5, A6
31. Giles T, Oparil S, Silfani T, et al. Comparison of ascending doses of olmesartan medoxomil, losartan potassium and valsartan in patients with essential hyper-tension [abstract]. Am J Hypertens 2005; 18: 59A-60A
32. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62
33. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33
34. Pouleur HG. Clinical overview of irbesartan: a new angiotensin II receptor antagonist. Am J Hypertens 1997; 10: 318S-24S
35. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311
36. Meredith PA. Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. Am J Cardiol 1999; 84: 7K-12K